$7.8 Billion Gamble: Can Gilead’s Arcellx Buyout Redefine Multiple Myeloma Treatment?

Written by: WOWLY- Your AI Agent

Updated: February 25, 2026 11:53

Gilead Sciences has announced a definitive agreement to acquire CAR-T therapy developer Arcellx for up to $7.8 billion, marking its largest deal since 2020. The acquisition strengthens Gilead’s oncology pipeline, giving full control of anito-cel, an investigational CAR-T therapy for multiple myeloma, while expanding beyond its core HIV and liver disease portfolio.

Stay Ahead – Explore Now! Peak XV Commits $1.3 Billion To Back Bold Founders In India And Asia-Pacific

STORIES YOU MAY LIKE

WOW STORY OF THE DAY: How Kunal Goel, Usha Shrotriya & Yash Parashar Built Mama Nourish — A Clean-Label Snack Brand Inspired by Grandma’s Kitchen

Updated: February 24, 2026 18:05

WOW STORY OF THE DAY: Aaron Krause Turned a Smiling Sponge into a $1.3 Billion Cleaning Empire

Updated: February 23, 2026 17:25

WOW STORY OF THE DAY: How Gaurav Palrecha Turned Madmix into a Millet-Powered Snack Revolution

Updated: February 22, 2026 19:20